COX-1
Summary
COX-1 (cyclooxygenase-1) is a constitutively expressed enzyme that converts arachidonic acid into prostaglandins and thromboxane A2, playing a key role in gastric mucosal protection, platelet aggregation, and renal blood flow maintenance. It is a key target of NSAIDs, whose inhibition of COX-1 explains many of their adverse effects.
Detail
COX-1 is one of two main cyclooxygenase isoforms (COX-1 and COX-2) that catalyze the conversion of arachidonic acid to prostaglandin H2, the precursor for various prostaglandins and thromboxane A2. COX-1 is constitutively expressed in most tissues, including the gastric mucosa, platelets, and kidneys, and is responsible for 'housekeeping' functions: maintaining the protective mucous/bicarbonate layer of the stomach, promoting platelet aggregation via thromboxane A2 production, and supporting renal perfusion through prostaglandin-mediated vasodilation of afferent arterioles.
Nonselective NSAIDs (e.g., aspirin, ibuprofen, naproxen, indomethacin) inhibit both COX-1 and COX-2. Aspirin irreversibly acetylates and inhibits COX-1 (and COX-2), accounting for its prolonged antiplatelet effect lasting the lifespan of the platelet (~7-10 days), since platelets lack nuclei and cannot synthesize new enzyme. This is the basis for low-dose aspirin's use in cardiovascular prophylaxis.
Inhibition of COX-1 is responsible for many classic NSAID adverse effects: gastric ulcers and GI bleeding (due to decreased protective prostaglandins like PGE2 and PGI2), acute kidney injury (due to decreased renal prostaglandin-mediated vasodilation, particularly in volume-depleted states or with ACE inhibitor co-administration), and bleeding risk (due to decreased thromboxane A2 and impaired platelet aggregation).
COX-2 selective inhibitors (e.g., celecoxib) were developed to reduce GI side effects by sparing COX-1, though they still carry cardiovascular risk and some renal toxicity since COX-2 also contributes to renal function and endothelial prostacyclin production. Understanding the COX-1 vs COX-2 distinction is essential for predicting NSAID adverse effect profiles and drug interactions on board exams.
Sources
- Katzung's Basic & Clinical Pharmacology
- First Aid for the USMLE Step 1
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
Reviewed by AnkiBoss editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.